AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

The latest report, Panic Attack Treatment Global Market Report 2025, brings light to the rapid growth of panic attack treatment market in recent years. The market size is expected to surge from $3.04 ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...

A study published in The BMJ compares the evidence around intermittent fasting and calorie restriction for weight loss. Prof Maik Pietzner, Chair in Health Data Modelling, Queen Mary University of ...

AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie Golden Ticket Comes to a ClosePress release2025-06-18 11:48AbbVie Golden Ticket ceremony at SmiLe Venture Hub.Lund, Sweden – The one-year AbbVie Golden Ticket program has officially concluded – ...

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Inflammatory Bowel Disease Treatment Market Size 2035 Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of th ...

The global biosimilar and biologics market is projected to grow from USD 561.7 billion in 2025 to USD 1,157.4 billion by 2035 ...